semaglutide timeline WEGOVY: Leading the Charge in Weight Loss Treatment Semaglutide Weight Loss Results 2026:

Trends Pharmacol Sci 38:749760

These variables, which were selected because they are likely to affect treatment outcomes, encompassed both demographic factors (region, sex, age at index date) and clinical history (baseline HbA1c, baseline weight, CVD in the past 365 day [coronary heart disease, cerebrovascular disease, peripheral vascular disease or heart failure], CharlsonDeyo risk index score), as well as index year, insurance type and previous receipt of oral antidiabetic medications

The strength of the TRIUMPH-1 data 28.3% weight loss at 80 weeks, 45.3% achieving bariatric-surgery-level outcomes gives Eli Lilly a compelling submission package

PS contributed to writingreview and editing